Analysis of Oritavancin In Vitro Activity against Enterococcal Isolates from US Medical Centers and Resistant Subsets.

Analysis of Oritavancin In Vitro Activity against Enterococcal Isolates from US Medical Centers and Resistant Subsets. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal
#116

Activity of Meropenem-Vaborbactam and Comparator Agents against Multidrug-Resistant Enterobacteriaceae Isolates from the United States Analyzed by Site of Infection.

Activity of Meropenem-Vaborbactam and Comparator Agents against Multidrug-Resistant Enterobacteriaceae Isolates from the United States Analyzed by Site of Infection. Lead author: M Castanheira, presented at ESMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#117

Spectrum of Activity of RX-P2382, a Novel Class of Bacterial Ribosome Inhibitor.

Spectrum of Activity of RX-P2382, a Novel Class of Bacterial Ribosome Inhibitor. Lead author: D Shortridge, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#46

Tedizolid In Vitro Activity against a Contemporary Challenge Collection of Multidrug-Resistant Enterococcal Clinical Isolates.

Tedizolid In Vitro Activity against a Contemporary Challenge Collection of Multidrug-Resistant Enterococcal Clinical Isolates. Lead author: CG Carvalhaes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#111

In Vitro Activity Evaluation of a Next-Generation Polymyxin, SPR206, against Non-Fermentative Gram-Negative Bacilli Responsible for Human Infections.

In Vitro Activity Evaluation of a Next-Generation Polymyxin, SPR206, against Non-Fermentative Gram-Negative Bacilli Responsible for Human Infections. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#80

Activity of an Investigational Polymyxin-B-Like Compound (SPR206) against a Set of Enterobacteriaceae Organisms Responsible for Human Infections.

Activity of an Investigational Polymyxin-B-Like Compound (SPR206) against a Set of Enterobacteriaceae Organisms Responsible for Human Infections. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#81

The Role of Whole Genome Sequencing on Post-Marketing Surveillance Programs: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam in the United States

The Role of Whole Genome Sequencing on Post-Marketing Surveillance Programs: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam in the United States. Lead author: H Sader, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#107

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. by Sader HS, Flamm RK, Dale GE, Rhomberg PR and Castanheira M published in J Antimicrob Chemother. 2018; 73: 2400-2404

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. by Pfaller MA, Mendes RE, Duncan LR, Flamm RK and Sader HS. published in J. Antimicrob. Chemother.: in press, 2018.

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). by Sader HS, Castanheira M, Mendes RE and Flamm RK published in J. Antimicrob. Chemother.: in press, 2018.